Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization
Antibodies (Abs) are the major component of the humoral immune response and a key player in vaccination. The precise Ab-mediated inhibitory mechanisms leading to in vivo protection against HIV have not been elucidated. In addition to the desired viral capture and neutralizing Ab functions, complex A...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2019-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2019.02968/full |
| _version_ | 1819050078768201728 |
|---|---|
| author | Bin Su Bin Su Stefania Dispinseri Valeria Iannone Tong Zhang Tong Zhang Hao Wu Hao Wu Raphael Carapito Seiamak Bahram Gabriella Scarlatti Christiane Moog Christiane Moog |
| author_facet | Bin Su Bin Su Stefania Dispinseri Valeria Iannone Tong Zhang Tong Zhang Hao Wu Hao Wu Raphael Carapito Seiamak Bahram Gabriella Scarlatti Christiane Moog Christiane Moog |
| author_sort | Bin Su |
| collection | DOAJ |
| description | Antibodies (Abs) are the major component of the humoral immune response and a key player in vaccination. The precise Ab-mediated inhibitory mechanisms leading to in vivo protection against HIV have not been elucidated. In addition to the desired viral capture and neutralizing Ab functions, complex Ab-dependent mechanisms that involve engaging immune effector cells to clear infected host cells, immune complexes, and opsonized virus have been proposed as being relevant. These inhibitory mechanisms involve Fc-mediated effector functions leading to Ab-dependent cellular cytotoxicity, phagocytosis, cell-mediated virus inhibition, aggregation, and complement inhibition. Indeed, the decreased risk of infection observed in the RV144 HIV-1 vaccine trial was correlated with the production of non-neutralizing inhibitory Abs, highlighting the role of Ab inhibitory functions besides neutralization. Moreover, Ab isotypes and subclasses recognizing specific HIV envelope epitopes as well as pecular Fc-receptor polymorphisms have been associated with disease progression. These findings further support the need to define which Fc-mediated Ab inhibitory functions leading to protection are critical for HIV vaccine design. Herein, based on our previous review Su & Moog Front Immunol 2014, we update the different inhibitory properties of HIV-specific Abs that may potentially contribute to HIV protection. |
| first_indexed | 2024-12-21T11:42:20Z |
| format | Article |
| id | doaj.art-87d399b0d8554506bbe7f8ca51e8167d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T11:42:20Z |
| publishDate | 2019-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-87d399b0d8554506bbe7f8ca51e8167d2022-12-21T19:05:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-12-011010.3389/fimmu.2019.02968457357Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond NeutralizationBin Su0Bin Su1Stefania Dispinseri2Valeria Iannone3Tong Zhang4Tong Zhang5Hao Wu6Hao Wu7Raphael Carapito8Seiamak Bahram9Gabriella Scarlatti10Christiane Moog11Christiane Moog12Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Key Laboratory for HIV/AIDS Research, Beijing, ChinaViral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Milan, ItalyViral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Milan, ItalyCenter for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Key Laboratory for HIV/AIDS Research, Beijing, ChinaCenter for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, ChinaBeijing Key Laboratory for HIV/AIDS Research, Beijing, ChinaINSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, FranceINSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, FranceViral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, San Raffaele Scientific Institute, Milan, ItalyINSERM U1109, LabEx TRANSPLANTEX, Fédération Hospitalo-Universitaire (FHU) OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, FranceVaccine Research Institute (VRI), Créteil, FranceAntibodies (Abs) are the major component of the humoral immune response and a key player in vaccination. The precise Ab-mediated inhibitory mechanisms leading to in vivo protection against HIV have not been elucidated. In addition to the desired viral capture and neutralizing Ab functions, complex Ab-dependent mechanisms that involve engaging immune effector cells to clear infected host cells, immune complexes, and opsonized virus have been proposed as being relevant. These inhibitory mechanisms involve Fc-mediated effector functions leading to Ab-dependent cellular cytotoxicity, phagocytosis, cell-mediated virus inhibition, aggregation, and complement inhibition. Indeed, the decreased risk of infection observed in the RV144 HIV-1 vaccine trial was correlated with the production of non-neutralizing inhibitory Abs, highlighting the role of Ab inhibitory functions besides neutralization. Moreover, Ab isotypes and subclasses recognizing specific HIV envelope epitopes as well as pecular Fc-receptor polymorphisms have been associated with disease progression. These findings further support the need to define which Fc-mediated Ab inhibitory functions leading to protection are critical for HIV vaccine design. Herein, based on our previous review Su & Moog Front Immunol 2014, we update the different inhibitory properties of HIV-specific Abs that may potentially contribute to HIV protection.https://www.frontiersin.org/article/10.3389/fimmu.2019.02968/fullHIV-1antibody functionsnon-neutralizing antibodiesFcR-mediated inhibitionADCC |
| spellingShingle | Bin Su Bin Su Stefania Dispinseri Valeria Iannone Tong Zhang Tong Zhang Hao Wu Hao Wu Raphael Carapito Seiamak Bahram Gabriella Scarlatti Christiane Moog Christiane Moog Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization Frontiers in Immunology HIV-1 antibody functions non-neutralizing antibodies FcR-mediated inhibition ADCC |
| title | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| title_full | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| title_fullStr | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| title_full_unstemmed | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| title_short | Update on Fc-Mediated Antibody Functions Against HIV-1 Beyond Neutralization |
| title_sort | update on fc mediated antibody functions against hiv 1 beyond neutralization |
| topic | HIV-1 antibody functions non-neutralizing antibodies FcR-mediated inhibition ADCC |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2019.02968/full |
| work_keys_str_mv | AT binsu updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT binsu updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT stefaniadispinseri updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT valeriaiannone updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT tongzhang updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT tongzhang updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT haowu updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT haowu updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT raphaelcarapito updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT seiamakbahram updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT gabriellascarlatti updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT christianemoog updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization AT christianemoog updateonfcmediatedantibodyfunctionsagainsthiv1beyondneutralization |